摘要
目的比较替吉奥（S-1）＋奥沙利铂和FOLFOX6方案辅助化疗在可切除Ⅱ／Ⅲ期胃癌围术期患者中的疗效及药物不良反应。方法回顾性分析可切除Ⅱ／Ⅲ期胃癌围术期辅助S-1＋奥沙利铂方案（A组）和FOLFOX6方案（B组）化疗的患者40例，比较两种辅助化疗方案的疗效、术后辅助化疗无疾病进展生存期、KPS评分及药物不良反应。结果两组的客观缓解率（objective response rate，ORR）差异无统计学意义（χ2=2．849，P〉0．05）。A组和B组的无疾病进展生存期分别为316．000天和341．000天，差异有统计学意义（χ2=5．566，P=0．018）。B组KPS评分明显低于A组（t=2．122，P=0．040）；B组的恶心呕吐发生率高于A组（χ2=4．800，P=0．028），两组患者的Ⅲ-Ⅳ级不良反应主要为血液系统毒性。结论可切除Ⅱ／Ⅲ期胃癌围术期辅助FOLFOX6方案化疗的中期疗效优于S-1＋奥沙利铂方案，但药物不良反应发生率高，KPS评分低。
Objective To evaluate the efficacy and toxicity of S-1 plus oxaliplatin versus FOLFOX6 as perioperative chemotherapy for resectable gastric cancer of stage II / III. Method 40 patients with resectable gastric cancer of stage II / III administered with S-1 plus oxaliplatin （group A） or FOLFOX6 （group B） as perioperative chemotherapy were analyzed retrospectively to compare the efficacy, progression-free survival （PFS） , KPS score and the toxicity of the two regimens. Result The difference was significant in respect of ORR （χ2 = 2. 849, P〉 0. 05 ） ; And the median time to progressionfree survival was 316 days vs 341 days （χ2 =5. 566, P=0. 018） for group A and B; and the KPS score of group B was obviously lower than that of group A （t = 2. 122, P= 0. 040）. As for the adverse reactions, nausea and vomiting were more common in group B than in group A （χ2 =4. 800, P=0. 028） ; and the most common toxic reaction was toxicity of hematological system in both groups. Conclusion The efficacy of FOLFOX6 is better than S-1 plus oxaliplatin, while the incidence of grade III-IV toxicity is higher, with relatively lower KPS score.
出处
《癌症进展》
2014年第1期70-74,92,共6页
Oncology Progress
